BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Reqorsa (Quaratusugene Ozeplasmid) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Reqorsa (Quaratusugene Ozeplasmid)\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05703971-2205@assetmemo.bio
DTSTAMP:20261121T005937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Reqorsa (Quaratusugene Ozeplasmid): Phase 1/2 readout est. (NCT0570
 3971)
DESCRIPTION:Reqorsa (Quaratusugene Ozeplasmid)\, phase 1/2\, Small Cell Lun
 g Cancer.\nStudy: Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Main
 tenance Therapy in ES-SCLC Patients\nEstimated primary completion: Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/quaratusugene
 -ozeplasmid#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05703971
URL:https://assetmemo.bio/drug/quaratusugene-ozeplasmid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04486833-2205@assetmemo.bio
DTSTAMP:20261121T005937Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Reqorsa (Quaratusugene Ozeplasmid): Phase 1/2 readout est. (NCT0448
 6833)
DESCRIPTION:Reqorsa (Quaratusugene Ozeplasmid)\, phase 1/2\, Non-Small Cell
  Lung Cancer.\nStudy: Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib i
 n Patients With Advanced Lung Cancer Who Progressed on Osimertinib\nEstima
 ted primary completion: March 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/quaratusugene-ozeplasmid#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04486833
URL:https://assetmemo.bio/drug/quaratusugene-ozeplasmid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
